Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network-Reference-Cited by-同舟云学术

Real‐world prevalence of the inclusion criteria for the LEADER trial: Data from a national general practice network

Published:2019-04-11 Issue:7 Volume:21 Page:1661-1667
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Hinton William¹,Feher Michael¹,Munro Neil¹,Walker Megan²,Lusignan Simon¹³^ORCID

Affiliation:

1. Department of Clinical and Experimental MedicineUniversity of Surrey Guildford UK

2. Medical Affairs Department, Novo Nordisk Ltd Gatwick UK

3. Royal College of General PractitionersResearch and Surveillance Centre London UK

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13710

Reference43 articles.

1. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

2. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). Guidance for industry‐diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 Diabetes.2008.https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed June 12 2018.

3. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

4. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

5. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. From diabetes to diverse domains: the multifaceted roles of GLP-1 receptor agonists;Molecular Biology Reports;2024-07-23

2. Systems Pharmacology and Network Analysis to Advance Pharmacogenomics and Precision Medicine Decisions in Type-2 Diabetes Therapy;Future Pharmacology;2023-03-17

3. Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study;Nature Medicine;2022-12-07

4. TriMaster: randomised double-blind crossover trial of a DPP4-inhibitor, SGLT2-inhibitor and thiazolidinedione to evaluate differential glycaemic response to therapy based on obesity and renal function;2022-10-05

5. Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes: Protocol for a Kidney End Points Real-world Study (COMBi-KID Study);JMIR Research Protocols;2022-07-19